Tonix Pharmaceuticals (NASDAQ:TNXP) investors are having a bad week. Hot off the heels of a devastating interim analysis from one of its late-stage clinical trials that looks all but doomed to end in failure, the stock’s price has fallen well below $1.
…

Click here to view the original article.